Cargando…

Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer

Cell identity is controlled by regulatory elements, such as promoters, enhancers, and insulators, within the genome. These regulatory elements interact in the nucleus and form tissue‐specific chromatin structures. Dysregulation of these elements and their interactions can lead to loss of cell identi...

Descripción completa

Detalles Bibliográficos
Autores principales: Okabe, Atsushi, Kaneda, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177786/
https://www.ncbi.nlm.nih.gov/pubmed/33728716
http://dx.doi.org/10.1111/cas.14884
_version_ 1783703449431441408
author Okabe, Atsushi
Kaneda, Atsushi
author_facet Okabe, Atsushi
Kaneda, Atsushi
author_sort Okabe, Atsushi
collection PubMed
description Cell identity is controlled by regulatory elements, such as promoters, enhancers, and insulators, within the genome. These regulatory elements interact in the nucleus and form tissue‐specific chromatin structures. Dysregulation of these elements and their interactions can lead to loss of cell identity and promote the development of diseases such as cancer. Tumor cells acquire aberrantly activated enhancers at oncogenic driver genes through various mechanisms. Small genomic changes such as mutations, insertions, and amplifications can form aberrant enhancers. Genomic rearrangements at the chromosomal level, including translocations and inversions, are also often observed in cancers. These rearrangements can result in repositioning of enhancers to locations near tumor‐type‐specific oncogenes. Chromatin structural changes caused by genomic or epigenomic changes lead to mis‐interaction between enhancers and proto‐oncogenes, ultimately contributing to tumorigenesis through activation of oncogenic signals. Additional epigenomic mechanisms can also cause aberrant enhancer activation, including those associated with overexpression of oncogenic transcription factors and the mutation of transcriptional cofactors. Exogenous viral DNA can also lead to enhancer aberrations. Here, we review the mechanisms underlying aberrant oncogene activation through enhancer activation and rewiring, both of which are caused by genomic or epigenomic alterations in non‐coding regions.
format Online
Article
Text
id pubmed-8177786
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-81777862021-06-15 Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer Okabe, Atsushi Kaneda, Atsushi Cancer Sci Review Articles Cell identity is controlled by regulatory elements, such as promoters, enhancers, and insulators, within the genome. These regulatory elements interact in the nucleus and form tissue‐specific chromatin structures. Dysregulation of these elements and their interactions can lead to loss of cell identity and promote the development of diseases such as cancer. Tumor cells acquire aberrantly activated enhancers at oncogenic driver genes through various mechanisms. Small genomic changes such as mutations, insertions, and amplifications can form aberrant enhancers. Genomic rearrangements at the chromosomal level, including translocations and inversions, are also often observed in cancers. These rearrangements can result in repositioning of enhancers to locations near tumor‐type‐specific oncogenes. Chromatin structural changes caused by genomic or epigenomic changes lead to mis‐interaction between enhancers and proto‐oncogenes, ultimately contributing to tumorigenesis through activation of oncogenic signals. Additional epigenomic mechanisms can also cause aberrant enhancer activation, including those associated with overexpression of oncogenic transcription factors and the mutation of transcriptional cofactors. Exogenous viral DNA can also lead to enhancer aberrations. Here, we review the mechanisms underlying aberrant oncogene activation through enhancer activation and rewiring, both of which are caused by genomic or epigenomic alterations in non‐coding regions. John Wiley and Sons Inc. 2021-05-01 2021-06 /pmc/articles/PMC8177786/ /pubmed/33728716 http://dx.doi.org/10.1111/cas.14884 Text en © 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Review Articles
Okabe, Atsushi
Kaneda, Atsushi
Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer
title Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer
title_full Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer
title_fullStr Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer
title_full_unstemmed Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer
title_short Transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer
title_sort transcriptional dysregulation by aberrant enhancer activation and rewiring in cancer
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177786/
https://www.ncbi.nlm.nih.gov/pubmed/33728716
http://dx.doi.org/10.1111/cas.14884
work_keys_str_mv AT okabeatsushi transcriptionaldysregulationbyaberrantenhanceractivationandrewiringincancer
AT kanedaatsushi transcriptionaldysregulationbyaberrantenhanceractivationandrewiringincancer